Justices Advised To Keep Law Clear In 'Skinny Label' Case

By Ryan Davis · March 10, 2026, 10:37 PM EDT

Several intellectual property groups have urged the U.S. Supreme Court to use a case involving "skinny labels" on generic drugs to set clear guidelines on what constitutes induced patent infringement, saying...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

Case Number

Court

Supreme Court

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

February 19, 2025

Recent Articles By Ryan

February 26, 2026
Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk
January 20, 2026
Justices To Clarify What's Fair Game With 'Skinny Labels'
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
December 23, 2025
Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'
December 19, 2025
Squires Issues 21 More Patent Review Denials
December 10, 2025
Apple Tells Fed. Circ. ITC Move Boosts Watch Case Appeal
December 03, 2025
USPTO Gets Earful On Plan To Restrict Patent Reviews
October 30, 2025
Fed. Circ. Explains Rule While Upholding Merck PTAB Loss
October 03, 2025
NIH Sets Patent License Policy Aimed At Promoting Access
September 15, 2025
Stewart Says New Policies Seek Fairness For Patent Owners